文献速递神经核医学核素与放射性配体治疗

68Ga-FAPI04与68Ga-DOTATATE PET/CT在多发性脑膜瘤患者中的对比

68 Ga-FAPI04 Versus 68 Ga-DOTATATE PET/CT in a Patient With Multiple Meningioma.
PubMed 文献 · Clin Nucl Med · 2023-03-06

本文报道一名61岁男性非典型世界卫生组织II级多发性脑膜瘤患者,经多次手术及外放疗后病情稳定2年,近期头痛复查MRI确认新发脑膜瘤病灶,因无法手术转诊行68Ga-DOTATATE PET/CT评估挽救性肽受体放射性核素治疗资格,并另行接受68Ga-FAPI04 PET/CT,显示多发性脑膜瘤病灶间成纤维细胞激活蛋白表达呈异质性、低至轻度。

要点

  • 61岁男性非典型WHO II级多发性脑膜瘤患者,多次手术及外放疗后稳定2年,近期MRI确认新发病灶。
  • 因无法手术,转诊行68Ga-DOTATATE PET/CT以评估挽救性肽受体放射性核素治疗资格。
  • 68Ga-FAPI04 PET/CT显示多发性脑膜瘤病灶成纤维细胞激活蛋白表达呈异质性、低至轻度。

核心结论

  • 68Ga-FAPI04 PET/CT显示该多发性脑膜瘤患者病灶的成纤维细胞激活蛋白表达呈异质性、低至轻度。

研究设计与样本

  • 本文为病例报告,报道一名61岁男性非典型世界卫生组织II级多发性脑膜瘤患者的68Ga-DOTATATE与68Ga-FAPI04 PET/CT影像表现。

主要发现

  • 患者经多次手术及外放疗后病情稳定2年,近期因频繁头痛复查MRI确认新发脑膜瘤病灶。
  • 患者无法手术,转诊行68Ga-DOTATATE PET/CT以确定挽救性肽受体放射性核素治疗资格。
  • 68Ga-FAPI04 PET/CT显示多发性脑膜瘤病灶间成纤维细胞激活蛋白表达呈异质性、低至轻度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present the 68 Ga-DOTATATE and 68 Ga-FAPI (fibroblast activation protein inhibitor) PET/CT findings of a 61-year-old man diagnosed with atypical World Health Organization grade II multiple meningiomas. The patient has been stable for 2 years following multiple surgeries and external radiotherapy because of recurring disease until he recently described frequent headaches, and a follow-up examination confirmed new meningioma lesions on MRI. However, the patient was inoperable and was referred for 68 Ga-DOTATATE PET/CT to determine eligibility for salvage peptide receptor radionuclide therapy. He also underwent fibroblast activation protein-targeted imaging using 68 Ga-FAPI04 PET/CT, which revealed heterogeneous, low to mild fibroblast activation protein expression across multiple meningioma lesions.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Denizmen D, Isik EG, Buyukkaya F, et al. 68 Ga-FAPI04 Versus 68 Ga-DOTATATE PET/CT in a Patient With Multiple Meningioma. Clin Nucl Med. 2023. PMID: 36881633. doi:10.1097/RLU.0000000000004617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。